Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

Yahoo Finance • 4 days ago

Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?

In September 2026, Biohaven Ltd. announced a clinical supply agreement with Regeneron Pharmaceuticals to test BHV-1530 in combination with cemiplimab (Libtayo) in patients with solid tumors, following earlier monotherapy and preclinical da... Full story

Yahoo Finance • 9 days ago

Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets

Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spen... Full story

Yahoo Finance • 10 days ago

Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks

Global bond yields recently hit multidecade highs, raising borrowing costs and putting pressure on many high growth sectors. When money gets more expensive, investors often look harder at balance sheets and valuations. That is where select... Full story

Yahoo Finance • 10 days ago

Why Regeneron (REGN) Stock Is Trading Lower Today

Why Regeneron (REGN) Stock Is Trading Lower Today What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 4% in the afternoon session after the biotechnology company expanded its immunology alliance with Sanofi on terms tha... Full story

Yahoo Finance • 10 days ago

Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls

Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled... Full story

Yahoo Finance • 11 days ago

Regeneron drug said to cut muscle loss when combined with Novo's semaglutide

[Doctor doing research in lab during COVID-19] Morsa Images * An experimental weight-loss drug being developed by Regeneron (REGN [https://seekingalpha.com/symbol/REGN]) used in combination with Novo Nordisk's (NVO [https://seekingalpha... Full story

Yahoo Finance • 11 days ago

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

Regeneron Pharmaceuticals, Inc. REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting prec... Full story

Yahoo Finance • 11 days ago

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

Sanofi Winthrop Industrie Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron,... Full story

Yahoo Finance • 18 days ago

Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts

Key Points Interested in Regeneron Pharmaceuticals, Inc.? Here are five stocks we like better. EYLEA HD is gaining momentum, accounting for roughly 60% of EYLEA franchise sales in the second quarter. Regeneron expects low- to mid-teens se... Full story

Yahoo Finance • 18 days ago

Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva

With 190 live customers and 14 top 20 biopharma commitments, Vault CRM is the fastest path to AI PLEASANTON, Calif., Sept. 23, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to r... Full story

Yahoo Finance • 20 days ago

1 S&P 500 Stock Worth Your Attention and 2 We Ignore

1 S&P 500 Stock Worth Your Attention and 2 We Ignore The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn't mean every stock is worth owning. Some companies face significant challenges, whether it's stagn... Full story

Yahoo Finance • 23 days ago

Trump set to announce MFN pricing for Medicaid in all states

[Rising prescription drug costs] PM Images/DigitalVision via Getty Images * President Trump on Friday will announce that Medicaid beneficiaries in all 50 states will benefit from "Most Favored Nation" pricing discounts for some prescrip... Full story

Yahoo Finance • 24 days ago

Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight

The expected launch of potential therapies such as Pozelimab +Cemdisiran (Regeneron Pharmaceuticals), Zaltenibart (OMS906; Novo Nordisk), Ruxoprubart (NM8074; NovelMed Therapeutics), NM5072 (NovelMed Therapeutics), ADX-038 (ADARx Pharmaceu... Full story

Yahoo Finance • 24 days ago

FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia

Bayer BAYRY announced that the FDA has approved a label expansion for kidney disease drug Kerendia (finerenone) for the treatment of adult patients with chronic kidney disease (CKD) associated with type one diabetes (T1D). The drug is a s... Full story

Yahoo Finance • 26 days ago

Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

The race for pharmaceutical dominance often centers on chronic disease management. For investors, deciding between Novo Nordisk (NYSE:NVO) and Regeneron Pharmaceuticals (NASDAQ:REGN) requires a close look at their unique market strengths.... Full story

Yahoo Finance • 27 days ago

Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight

The bispecifics market is anticipated to experience substantial growth in the coming years. This growth is driven by the rising incidence of chronic diseases, technological advancements, increasing regulatory approvals, strategic collabora... Full story

Yahoo Finance • last month

Big Short Billionaire Goes Long: Michael Burry Avoids AI, Bets on Beaten own Stocks Instead

Quick Read Burry holds UNH and REGN as his two largest call positions, with REGN delivering Q2 EPS of $14 against an $8 consensus estimate. Burry calls LULU 'screaming cheap' despite a 52% year-to-date drop, pointing to its strong balance... Full story

Yahoo Finance • last month

IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?

Quick Read IBB surged 26% over three months versus SPY's 4%, as big pharma's price-insensitive buyouts of patent-cliff replacements rewarded IBB holders. XBI's equal-weight design returned 34% YTD versus IBB's 26%, making it the higher-to... Full story

Yahoo Finance • last month

2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB

Company Logo Complement Inhibitors MarketComplement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecu... Full story

Yahoo Finance • last month

Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials

Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here. The Sound Shore Fund's Investor Class (SSHFX) and Institutional Class (SSHVX) rose 1... Full story